

Opportunities for Advances in CLL - Emil J Freireich Leukemia Hematology Grand Rounds - 9/18/2024
9/18/2024 8:00:00 AM - 9/18/2024 9:00:00 AM

By texting in your attendance, you will be awarded the maximum number of CE credits. If you wish to claim less than the maximum CE credits, please contact ContinuingEducation@mdanderson.org

Target Audience:

Professions: Physician (MD or DO), Nurse - RN, Pharmacist, Physician Associate, Student or Trainee, Nurse - APRN

Learning Objectives:

- 1 Discuss new therapies with regards to their mechanisms of action, rationale, toxicity and activity in hematological disorder
- 2 Apply new strategies for treating Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, and other Hematological cancer in practice to improve patient care
- 3 Assess patient management based on treatment programs/changes in treatment regimens for hematological disorders
- 4 Discuss patient management with regards to complications of chemotherapy and immunosuppression & strategies to counteract these complications
- 5 Discuss new knowledge on molecular etiology of leukemia, as it relates to the development of novel therapies

Accreditation:



In support of improving patient care, The University of Texas MD Anderson Cancer Center, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation:

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support:

No commercial support has been received for this activity.

Disclosure of Financial Relationships:

The University of Texas MD Anderson Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty & Planner Disclosure:

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Hagop M. Kantarjian, MD	Activity Co-Director	Grant or research support-AbbVie Inc. Grant or research support-Amgen Inc. Grant or research support-Pfizer

		Inc. Grant or research support-Takeda Consulting Fee-AbbVie Inc. Consulting Fee-Amgen Inc. Consulting Fee-Bristol-Myers Squibb Company Consulting Fee-Pfizer Inc. Consulting Fee-Takeda - 09/05/2024
Farhad Ravandi, MD	Activity Director	Honoraria-AbbVie Inc. (Relationship has ended) Honoraria-Astellas Scientific and Medical Affairs, Inc. Honoraria-Celgene Corporation Honoraria-Bristol-Myers Squibb Foundation Honoraria-Genentech, Inc. (Relationship has ended) Honoraria-Pfizer Inc. (Relationship has ended) Honoraria-Taiho Pharmaceutical (Relationship has ended) Grant or research support-Bristol-Myers Squibb Company Grant or research support-Amgen Inc. (Relationship has ended) Grant or research support-AbbVie Inc. (Relationship has ended) Consulting Fee-Syndax - 09/05/2024
William G Wierda, MD,PhD	Faculty	Nothing to disclose - 01/04/2024
Abhishek Maiti, MD	Activity Co-Director	Grant or research support-LinBio Sciences - 03/19/2024
Danielle Hammond, MD	Activity Co-Director	Nothing to disclose - 09/05/2024